Evidence map›Paper›PMID 27892946›Full record

Trial reportBone marrow transplantation2017

First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.

D Ghez, C Fortpied, N Mounier, P Carde, A Perrot, H Khaled, S Amorim, S Ramadan, F L Bras, M Erlanson and 6 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

D GhezDepartment of Hematology, Gustave Roussy, Villejuif, France.
C FortpiedEORTC Headquarters, Brussels, Belgium.
N MounierDepartment of Onco-Hematology, CHU l'Archet, Nice, France.
P CardeDepartment of Hematology, Gustave Roussy, Villejuif, France.
A PerrotDepartment of Hematology, CHU Nancy-Brabois, Vandoeuvre Les Nancy, France.
H KhaledDepartment of Medical Oncology, National Cancer Institute, Cairo, Egypt.
S AmorimDepartment of Oncology and Hematology, Hopital Saint-Louis APHP, Université Paris Diderot, Paris, France.
S RamadanEORTC Headquarters, Brussels, Belgium.
F L BrasUnité Hémopathies Lymphoïdes, Hôpital Henri Mondor, Creteil, France.
M ErlansonDepartment of Oncology, Umea Universitet, Umea, Sweden.
C HerbauxDepartment of Clinical Hematology, Hôpital Claude Huriez, Université de Lille 2, Lille, France.
J-P MarolleauDepartment of Hematology, CHU Amiens, Université Picardie Jules Verne, Amiens, France.
E Nicolas-VirelezierDepartment of Hematology, Leon Bérard Cancer Center, Lyon, France.
O CasasnovasDepartment of Hematology, CHU Dijon, Dijon, France.
A Stamatoullas-BastardDepartment of Hematology, Centre Henri Becquerel, Rouen, France.
C FerméDepartment of Hematology, Gustave Roussy, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell MobilizationHodgkin DiseasePeripheral Blood Stem Cell TransplantationAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsAutograftsDisease-Free SurvivalHumansMiddle AgedStem CellsSurvival Rate

Identifiers

PMID27892946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.